Human epidermal growth factor receptor 2-low is not a distinct subgroup in breast cancer patients undergoing neoadjuvant chemotherapy
Introduction: Breast cancer is a heterogeneous disease, and patients with low expression of human epidermal growth factor receptor 2 (HER2) benefit from antibody-drug conjugate therapies. Objective: To investigate the association between HER2-low status and survival and pathologic complete response (pCR) in breast can...